Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
A Phase III, Randomized, Observer-blind, Controlled, Multi-center Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One and Two Intramuscular Doses of Influenza Vaccine Versus Control Vaccines in Healthy Subject Aged 6 to <72 Months
Sponsor: Novartis
A PHASE3 clinical study on Influenza, Human, this trial is completed. The trial is conducted by Novartis and has accumulated 7 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis
- Novartis Vaccines
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalen Wasseralfingen, Germany , Berlin, Germany , Bindlach, Germany , Binngen Rhein, Germany , Bobingen, Germany , Bochum, Germany , Braunfels, Germany , Bretten, Germany , Brunsbüttel, Germany , Detmold, Germany and 64 more locations